<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Reports have shown that anticardiolipin (aCL) antibodies present in patients with <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> are dependent on the cofactor,beta2 <z:chebi fb="2" ids="17089">glycoprotein</z:chebi> I (beta2 GPI), as opposed to aCL antibodies seen in <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious diseases</z:e> such as <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e>, HIV <z:hpo ids='HP_0012115'>hepatitis</z:hpo> C, etc </plain></SENT>
<SENT sid="1" pm="."><plain>The assay for anti-beta2GPI antibodies has been reported to be more specific for <z:e sem="disease" ids="C0085278" disease_type="Disease or Syndrome" abbrv="">antiphospholipid syndrome</z:e> (APS) </plain></SENT>
<SENT sid="2" pm="."><plain>However, the prevalence of these antibodies in diseases such as <z:e sem="disease" ids="C0023281" disease_type="Disease or Syndrome" abbrv="">leishmaniasis</z:e> and <z:e sem="disease" ids="C0023364" disease_type="Disease or Syndrome" abbrv="">leptospirosis</z:e> remains unknown </plain></SENT>
<SENT sid="3" pm="."><plain>The aim of the present study was determine the prevalence of antibodies to <z:chebi fb="0" ids="28494">cardiolipin</z:chebi> and to beta2GPI in patients with different <z:e sem="disease" ids="C0009450" disease_type="Disease or Syndrome" abbrv="">infectious diseases</z:e>, including <z:e sem="disease" ids="C0023364" disease_type="Disease or Syndrome" abbrv="">leptospirosis</z:e>, <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> and <z:e sem="disease" ids="C0023281" disease_type="Disease or Syndrome" abbrv="">leishmaniasis</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: Samples from patients with <z:e sem="disease" ids="C0023290" disease_type="Disease or Syndrome" abbrv="">Kala-azar</z:e> (<z:e sem="disease" ids="C0023290" disease_type="Disease or Syndrome" abbrv="">visceral leishmaniasis</z:e>), <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> or <z:e sem="disease" ids="C0023364" disease_type="Disease or Syndrome" abbrv="">leptospirosis</z:e> were tested for IgG and IgM anticardiolipin and IgG anti-beta2GPI antibodies by ELISA </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: In patients with <z:e sem="disease" ids="C0023290" disease_type="Disease or Syndrome" abbrv="">Kala-azar</z:e> the prevalence of IgG aCL, IgM aCL and anti-beta2GPI was 6% (2/30), 3% (1/30) and 53% (16/30), respectively </plain></SENT>
<SENT sid="6" pm="."><plain>In <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> the prevalence was 18% (14/74), 13% (10/74) and 10% (8/70), respectively </plain></SENT>
<SENT sid="7" pm="."><plain>In <z:e sem="disease" ids="C0023364" disease_type="Disease or Syndrome" abbrv="">leptospirosis</z:e> the frequency of these antibodies was 23% (9/39), 10% (4/39) and 17% (6/34), respectively </plain></SENT>
<SENT sid="8" pm="."><plain>There was no statistical correlation between aCL and anti-beta2GPI antibodies in these diseases </plain></SENT>
<SENT sid="9" pm="."><plain>DISCUSSION: This study clearly shows a significant prevalence of anti-beta2GPI antibodies in <z:e sem="disease" ids="C0023364" disease_type="Disease or Syndrome" abbrv="">leptospirosis</z:e> and <z:e sem="disease" ids="C0023281" disease_type="Disease or Syndrome" abbrv="">leishmaniasis</z:e> and <z:e sem="disease" ids="C0039128" disease_type="Disease or Syndrome" abbrv="">syphilis</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>This indicates that the assay for antibeta2GPI antibodies should be thoroughly validated before it is introduced as a definitive tool for the diagnosis of APS, testing a larger number of sera from patients with a wider range of clinical conditions </plain></SENT>
</text></document>